References
- Monath TP, Seligman SJ, Robertson JS, et al. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine. 2015;33(1):62–72.
- Halstead SB. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine. 2013;31(41):4501–4507.
- Capeding MR, Tran NH, Hadinegoro SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384(9951):1358–1365.
- Villar L, Dayan GH, Arredondo-García JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2015;372(2):113–123.
- Hadinegoro SR, Arredondo-García JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med. 2015;373(13):1195–1206. doi:10.1056/NEJMoa1506223. Epub 2015 Jul 27.
- Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380(9853):1559–1567.
- Guy B, Barrere B, Malinowski C, et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine. 2011;29(42):7229–7241.
- Wilder-Smith A. Dengue vaccines: dawning at last? Lancet. 2014;384(9951):1327–1329.
- Gubler D. 70 years on: progress in dengue vaccine development. Vaccine Companion. 2011;4:1–3.
- Leo YS, Wilder-Smith A, Archuleta S, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: phase II randomized controlled trial in Singapore. Hum Vaccin Immunother. 2012;8(9):1259–1271.
- Dorigatti I, Aguas R, Donnelly CA, et al. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia. Vaccine. 2015;33(31):3746–3751.
- Anderson KB, Gibbons RV, Cummings DA, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis. 2014;209(3):360–368.
- Guzmán MG, Kourí G, Valdés L, et al. Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks. Rev Panam Salud Publica. 2002;11(4):223–227.
- RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386(9988):31–45.
- Murray NE, Quam MB, Wilder-Smith A. Epidemiology of dengue: past, present and future prospects. Clin Epidemiol. 2013;5:299–309.
- Limkittikul K, Brett J, L’Azou M. Epidemiological trends of dengue disease in Thailand (2000–2011): a systematic literature review. PLoS Negl Trop Dis. 2014;8(11):e3241.
- Teixeira MG, Siqueira JB Jr, Ferreira GL, et al. Epidemiological trends of dengue disease in Brazil (2000–2010): a systematic literature search and analysis. PLoS Negl Trop Dis. 2013;7(12):e2520.
- SISTEMA DE INFORMAÇÃO DE AGRAVOS DE NOTIFICAÇÃO - SINAN [Internet]. 2015. [ cited 2015 Oct 7]. Available from: http://dtr2004.saude.gov.br/sinanweb/.
- Gessner BD, Feikin DR. Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy. Vaccine. 2014;32(26):3133–3138.
- Kelly H, Attia J, Andrews R, et al. The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. Vaccine. 2004;22(17–18):2192–2198.
- Wilder-Smith A, Gubler DJ. Public health. Dengue vaccines at a crossroad. Science. 2015;350(6261):626–627.
- SAGE Working Group on Dengue Vaccines and Vaccination [Internet]. 2015. [ cited 2015 Oct 7]. Available from: http://www.who.int/immunization/policy/sage/sage_wg_dengue_mar2015/en/.